Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)GlobeNewsWire • 10/03/23
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare ConferenceGlobeNewsWire • 09/20/23
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 InhibitorGlobeNewsWire • 09/18/23
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/07/23
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 08/07/23
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)GlobeNewsWire • 06/13/23
Aclaris Therapeutics to Participate in Two June Healthcare Investor ConferencesGlobeNewsWire • 06/02/23
Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 05/08/23
Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023GlobeNewsWire • 05/02/23
Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual ConferenceGlobeNewsWire • 03/27/23
Aclaris Therapeutics: Potential Speculative Play After Zunsemetinib Misses Mark On Hidradenitis SuppurativaSeeking Alpha • 03/09/23
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 02/23/23
Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma ConferenceGlobeNewsWire • 02/09/23
Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater ChinaGlobeNewsWire • 11/29/22